A carregar...

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Itatani, Yoshiro, Kawada, Kenji, Yamamoto, Takamasa, Sakai, Yoshiharu
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5979390/
https://ncbi.nlm.nih.gov/pubmed/29670046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19041232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!